Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

類似資料

• Long term follow up of treatment with ibrutinib and rituximab (IR) in patients with high-risk Chronic Lymphocytic Leukemia (CLL)
  著者:: Jain, Preetesh, 等
  出版事項: (2016)
• Long-term Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) who Discontinue Ibrutinib
  著者:: Jain, Preetesh, 等
  出版事項: (2017)
• Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy
  著者:: Schliffke, Simon, 等
  出版事項: (2018)
• Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
  著者:: Jain, Preetesh, 等
  出版事項: (2015)
• Complex Karyotype is a Stronger Predictor than Del(17p) for Inferior Outcome in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens
  著者:: Thompson, Philip A., 等
  出版事項: (2015)